Evidence map›Paper›PMID 39192980›Full record

ReviewFrontiers in immunology2024

NK cell based immunotherapy against oral squamous cell carcinoma.

Ying Zhang, Jianming Xie, Haoran Wu, Jinhui Huang, Danna Zheng, Shaotong Wang, Xueqiang Jia, Zongzhong He, Ying Gong, Linling Ju and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ying ZhangDepartment of Stomatology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Jianming XieDepartment of Otolaryngology & Head and Neck Surgery, Anyuan People's hospital, Ganzhou, China.
Haoran WuSouthern Medical University, Guangzhou, Guangdong, China.
Jinhui HuangSouthern Medical University, Guangzhou, Guangdong, China.
Danna ZhengSouthern Medical University, Guangzhou, Guangdong, China.
Shaotong WangSouthern Medical University, Guangzhou, Guangdong, China.
Xueqiang JiaSouthern Medical University, Guangzhou, Guangdong, China.
Zongzhong HeDepartment of Transfusion Medicine, General Hospital of Southern Theatre Command, Guangzhou, Guangdong, China.
Ying GongDepartment of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Linling JuMedical School of Nantong University, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Qiurong SunDepartment of Stomatology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral squamous cell carcinoma (OSCC), a major subtype of head and neck cancers, presents significant challenges due to its aggressive feature and limited therapeutic efficacy of conventional treatments. In response to these challenges, Natural Killer (NK) cells, a vital component of the innate immune system, are being explored for their therapeutic potential in OSCC due to their inherent ability to target and eliminate cancer cells without prior sensitization. This review uniquely focuses on the evolving role of NK cells specifically in OSCC, incorporating recent advancements in CAR-NK cell engineering and personalized therapy approaches that have not been comprehensively covered in previous reviews. The mechanisms through which NK cells exert cytotoxic effects on tumor cells include direct killing through the engagement of natural cytotoxic receptors and antibody-dependent cellular cytotoxicity (ADCC), making them promising agents in cancer immunotherapy. Additionally, the article explores recent advancements in engineering NK cells to enhance their antitumor activity, such as the modification with chimeric antigen receptors (CARs) to target specific tumor antigens. Clinical implications of NK cell-based therapies, including the challenges of integrating these treatments with existing protocols and the potential for personalized therapy, are examined. The review highlights the promise of NK cell therapies in improving outcomes for OSCC patients and outlines future directions for research in this dynamic field of oncological immunotherapy.

Indexed as

Killer Cells, NaturalMouth NeoplasmsAnimalsCarcinoma, Squamous CellHumansImmunotherapyImmunotherapy, AdoptiveReceptors, Chimeric AntigenReceptors, Chimeric AntigenCAR-NKimmunotherapynatural killer cellsoral squamous cell carcinomatumor microenvironment

Identifiers

PMID39192980
PMCPMC11347299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.